Clay Thorp - Net Worth and Insider Trading
Clay Thorp Net Worth
The estimated net worth of Clay Thorp is at least $29 Million dollars as of 2024-12-27. Clay Thorp is the 10% Owner of G1 Therapeutics Inc and owns about 3,237,711 shares of G1 Therapeutics Inc (GTHX) stock worth over $23 Million. Clay Thorp is the Director of Clearside Biomedical Inc and owns about 3,585,562 shares of Clearside Biomedical Inc (CLSD) stock worth over $3 Million. Clay Thorp is also the Director of Vigil Neuroscience Inc and owns about 1,559,030 shares of Vigil Neuroscience Inc (VIGL) stock worth over $3 Million. Besides these, Clay Thorp also holds PhaseBio Pharmaceuticals Inc (PHASQ) . Details can be seen in Clay Thorp's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Clay Thorp has not made any transactions after 2023-09-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Clay Thorp
Clay Thorp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Clay Thorp owns 4 companies in total, including Clearside Biomedical Inc (CLSD) , PhaseBio Pharmaceuticals Inc (PHASQ) , and G1 Therapeutics Inc (GTHX) among others .
Click here to see the complete history of Clay Thorp’s form 4 insider trades.
Insider Ownership Summary of Clay Thorp
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CLSD | Clearside Biomedical Inc | 2023-09-25 | director & 10 percent owner |
| PHASQ | PhaseBio Pharmaceuticals Inc | 2021-08-18 | director |
| GTHX | G1 Therapeutics Inc | 2018-05-30 | 10 percent owner |
 | | 2022-05-17 | director |
Clay Thorp Latest Holdings Summary
Clay Thorp currently owns a total of 4 stocks. Among these stocks, Clay Thorp owns 3,237,711 shares of G1 Therapeutics Inc (GTHX) as of May 30, 2018, with a value of $23 Million and a weighting of 79.63%. Clay Thorp owns 3,585,562 shares of Clearside Biomedical Inc (CLSD) as of September 25, 2023, with a value of $3 Million and a weighting of 11.47%. Clay Thorp also owns 1,559,030 shares of Vigil Neuroscience Inc (VIGL) as of May 17, 2022, with a value of $3 Million and a weighting of 8.9%. The other 1 stocks PhaseBio Pharmaceuticals Inc (PHASQ) have a combined weighting of 0% among all his current holdings.
Latest Holdings of Clay Thorp
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| GTHX | G1 Therapeutics Inc | 2018-05-30 | 3,237,711 | 7.15 | 23,149,634 |
| CLSD | Clearside Biomedical Inc | 2023-09-25 | 3,585,562 | 0.93 | 3,334,573 |
| VIGL | Vigil Neuroscience Inc | 2022-05-17 | 1,559,030 | 1.66 | 2,587,990 |
| PHASQ | PhaseBio Pharmaceuticals Inc | 2021-08-18 | 32,943 | 0.00 | 3 |
Holding Weightings of Clay Thorp
Clay Thorp Form 4 Trading Tracker
According to the SEC Form 4 filings, Clay Thorp has made a total of 0 transactions in G1 Therapeutics Inc (GTHX) over the past 5 years. The most-recent trade in G1 Therapeutics Inc is the sale of 800,000 shares on May 30, 2018, which brought Clay Thorp around $38 Million.
According to the SEC Form 4 filings, Clay Thorp has made a total of 4 transactions in Clearside Biomedical Inc (CLSD) over the past 5 years, including 2 buys and 2 sells. The most-recent trade in Clearside Biomedical Inc is the acquisition of 10,000 shares on September 25, 2023, which cost Clay Thorp around $8,600.
According to the SEC Form 4 filings, Clay Thorp has made a total of 3 transactions in Vigil Neuroscience Inc (VIGL) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Vigil Neuroscience Inc is the acquisition of 36,695 shares on May 17, 2022, which cost Clay Thorp around $104,581.
More details on Clay Thorp's insider transactions can be found in the Insider Trading History of Clay Thorp table.Insider Trading History of Clay Thorp
- 1
Clay Thorp Trading Performance
GuruFocus tracks the stock performance after each of Clay Thorp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Clay Thorp is 4.91%. GuruFocus also compares Clay Thorp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Clay Thorp within 3 months outperforms 5 times out of 11 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Clay Thorp's insider trading performs compared to the benchmark.
Performance of Clay Thorp
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -4.92 | | | | | |
| Relative Return to S&P 500(%) | -2.19 | | | | | |
Clay Thorp Ownership Network
Clay Thorp Owned Company Details
What does Clearside Biomedical Inc do?
Who are the key executives at Clearside Biomedical Inc?
Clay Thorp is the director & 10 percent owner of Clearside Biomedical Inc. Other key executives at Clearside Biomedical Inc include 10 percent owner Bradford T Whitmore , Chief Financial Officer Charles A. Deignan , and Chief Medical Officer Thomas Ciulla .
Clearside Biomedical Inc (CLSD) Insider Trades Summary
Over the past 18 months, Clay Thorp made 1 insider transaction in Clearside Biomedical Inc (CLSD) with a net purchase of 10,000. Other recent insider transactions involving Clearside Biomedical Inc (CLSD) include a net purchase of 90,000 shares made by , a net purchase of 580,222 shares made by Bradford T Whitmore , and a net purchase of 100,000 shares made by Anthony S Gibney .
In summary, during the past 3 months, insiders sold 0 shares of Clearside Biomedical Inc (CLSD) in total and bought 36,500 shares, with a net purchase of 36,500 shares. During the past 18 months, 30,900 shares of Clearside Biomedical Inc (CLSD) were sold and 798,035 shares were bought by its insiders, resulting in a net purchase of 767,135 shares.
Clearside Biomedical Inc (CLSD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Clearside Biomedical Inc Insider Transactions
Clay Thorp Mailing Address
Above is the net worth, insider trading, and ownership report for Clay Thorp. You might contact Clay Thorp via mailing address: C/o Hatteras Venture Partners Iii, Lp, 280 S. Mangum St., Suite 350, Durham Nc 27701.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
